Cellular immune responses to human immunodeficiency virus type 1 (HIV-1) infection, particularly in vivo responses, have been difficult to study in large patient cohorts because of technical impediments. By use of small peptide fragments of the HIV-1 gp120 third variable loop, the CD4 T lymphocyte epitopes of 2 HIV-infected persons were mapped using a cutaneous delayed-type hypersensitivity (DTH) assay. The in vivo DTH responses correlated with epitopes previously identified in vitro using CD4 T lymphocyte lines. The ability to determine CD4 T lymphocyte epitopes in large cohorts of patients using this simple in vivo technique would provide important diagnostic and prognostic data regarding effective immunoregulation of HIV-1. This technique should have broad applicability in HIV vaccine development and in the investigation of other immune-mediated human diseases.
Delayed-type hypersensitivity (DTH) skin testing has been
We have previously identified T lymphocyte epitopes in the HIV-1 gp120 protein from HIV-1-infected volunteers particiused for nearly 100 years as a diagnostic tool for numerous infectious diseases, and more recently, as an important criterion pating in a phase II gp160 vaccine therapy trial using HIV-1 envelope-specific CD4 T lymphocyte lines [6] . In a subsequent in the evaluation of suspected immunodeficiencies [1] . Microbial recall antigen responsiveness by DTH testing has been study [7] , fine epitope mapping of the third variable (V3) loop sequence was performed using CD4 cell lines and a series of shown to be an independent predictor of human immunodeficiency virus type 1 (HIV-1) disease progression [2] [3] [4] . The truncated V3 loop peptides in 4 persons. However, these in vitro techniques for CD4 epitope mapping are labor-intensive prognostic value of DTH responses to specific HIV proteins is currently under investigation. Preliminary reports suggest that and have uncertain in vivo sensitivity and specificity. Using 2 of these HIV-infected volunteers, selected because of their acquisition of DTH reactivity to an HIV-1 whole inactivated vaccine may confer a more favorable prognosis [5] . In order nonoverlapping CD4 cell epitopes in the V3 region, we investigated whether DTH reactivity to peptide constituents of the to define and exploit potentially protective cellular immune responses in a diverse human population, it is necessary to gp120 protein could be used to precisely determine their epitopes. identify the individual epitopes that contribute to the whole protein response.
Materials and Methods
Subjects. Two HIV-1-infected volunteers, 1 man and 1 [8] , and the complete linear sequence (LAI-D: TRPNNNTRKSIRdescribed [6] . A total of 3 1 10 4 T cells was incubated in a 96-well flat bottom plate with 1 1 10 5 irradiated autologous peripheral IQRGPGRAFVTIGKIGNMRQAH) of the V3 loop. The underlined sections indicate the presence of the volunteers' CD4 cell blood mononuclear cells (PBMC) and each peptide at 5 mg/mL, rgp120, or medium alone. After 2 days of incubation, the cells complete epitope sequence in the peptides. These V3 loop peptides (HIV-1 LAI sequence, matching the rgp160 vaccine) were manuwere pulsed with 1.67 mCi/well [ 3 H]thymidine for 18 h, harvested, and counted. factured under good laboratory practice standards using standard FMOC technology and then purified at a facility under good manu-PBMC assay. A total of 1 1 10 5 PBMC was incubated in a 96-well round bottom plate with each peptide at 50, 5, or 0.5 mg/ facturing practices using reverse-phase high-pressure liquid chromatography. Analytical methods necessary to support the identity mL ( figure 1B , only a 5-mg/mL concentration was used), rgp160, or medium alone. The assay was performed using triplicate wells and purity of the peptides were used as part of the Investigational New Drug Application 6306. The V3 loop peptides were reconstifor each peptide or protein. ping CD4 cell epitopes in the V3 region, were selected for this loop peptides was required to elicit a response. Punch biopsies (3 proof of concept study. Four peptides were selected for testing: mm) were taken from three sites (as described above), placed LAI-A, the amino half of the V3 sequence, containing the in in a formaldehyde fixative, and processed according to standard vitro epitope for volunteer 2; LAI-B, the carboxy half of the techniques. Paraffin-embedded sections were stained with hema-V3 sequence, containing the in vitro epitope for volunteer 1; toxylin-eosin or OPD4. , the crown of the V3 sequence, containing neither CD4 cell line proliferation assay. A gp120-specific CD4 T lymphocyte line from volunteer 2 was developed as previously complete epitope; and LAI-D, the complete linear V3 sequence, Figure 1 . Proliferative responses induced by third variable (V3) loop peptides before and at time of delayed-type hypersensitivity skin test protocol. A, gp120-specific CD4 T lymphocyte line from volunteer 2 (6 months prior to skin testing) proliferated in response to peptides LAI-A and LAI-D and recombinant (r) gp120 protein, as predicted by past in vitro epitope mapping [7] . B, Peripheral blood mononuclear cells (PBMC) from volunteer 1 (3 months prior to skin testing) proliferated in response to peptides LAI-B and LAI-D and rgp160 protein, as predicted by past in vitro epitope mapping [7] , thus confirming biologic activity of peptides. C, PBMC from volunteer 2 (day of skin testing) did not adequately define T lymphocyte epitope despite proliferation to entire rgp160 protein and recall antigens. D, PBMC from volunteer 1 (day of skin testing) did not adequately define T lymphocyte epitope despite proliferation to entire rgp160 protein. Data are expressed as lymphocyte stimulation index (LSI) (specific proliferation/background proliferation). Horizontal bars represent LSI §3 (standard antigen specificity in such assays). C and D, Nos. in parentheses represent antigen concentration in mg/mL. containing the in vitro epitopes of both volunteers. The study sensitivity. Volunteer 2 never demonstrated a PBMC proliferative response to any of the V3 loop peptides. PBMC from incorporated internal positive and negative peptide controls by injecting both volunteers with each of the four peptides; each volunteer 2 immediately prior to skin test application failed to proliferate in response to the V3 peptides despite a strong volunteer was predicted to respond to two of the V3 loop peptides. Two standard microbial recall antigens, tetanus toxoid proliferative response to the rgp160 protein ( figure 1C ). Volunteer 1 had variable PBMC proliferative results. PBMC from and candida, and 0.9% saline were used as additional positive and negative controls, respectively. volunteer 1 obtained Ç3 months prior to the skin test proliferated in response to the V3 loop peptides as predicted (figure The V3 loop peptides and controls were injected intradermally in a fashion identical to clinical tuberculin and anergy 1B), but PBMC obtained immediately prior to skin test application failed to provide fully informative results, despite peptide testing. The results (figures 2, 3) were reported 48 h after injection, the typical interval for maximal human DTH reacdose titration and an adequate response to the rgp160 protein ( figure 1D ). These data suggest that PBMC proliferative retions. The clinical course of the peptide-induced induration was comparable to that seen with the standard recall antigens. The sponses may not always be the most sensitive surrogate for determining expanded in vivo CD4 cell populations. photographs ( figure 2A, B) of the skin test readings demonstrate the simplicity of this technique and document that the V3 loop peptide responses are qualitatively and quantitatively Discussion similar to the standard tetanus toxoid response.
Both volunteers responded to the DTH skin test as predicted Using small peptides in a DTH assay, we demonstrated that cellular epitopes could be accurately identified in humans. Deby previous in vitro techniques (figures 1A, B, 3); volunteer 1 responded to V3 loop peptides LAI-B and LAI-D and volunteer spite studies in mice [11, 12] and guinea pigs [13, 14] that have demonstrated the feasibility of using small peptides to 2 responded to LAI-A and LAI-D. Neither volunteer responded to saline and LAI-P18, which lacked the predicted epitopes.
generate DTH-like reactions, there has been a paucity of work in humans. Although one previous study [15] reported a human Both subjects had V3 loop peptide responses of the same magnitude and character as their own tetanus toxoid responses, alresponding in a DTH-like skin test assay to two allergenic rye grass peptides that matched the in vitro PBMC proliferative though volunteer 1 had more vigorous responses in general (figure 3) . The threshold dose for response differed between the 2 response, the substantial clinical utility of this technique has not been realized. We demonstrate in this study that peptidesubjects: Volunteer 1 responded to 0.5-mg doses of the peptides, while volunteer 2 required 5-mg doses for measurable reactivity.
based DTH skin testing, typical in clinical course as well as histology, can be applied to HIV-infected persons in a systemEach of the positive peptide responses was of a magnitude (10-20 mm of induration) that was easily measured and distinct from atic way to clearly demarcate epitopes that are in close proximity. Having demonstrated the clinical potential of peptide-based the negative responses. Volunteer 2 also had moderate cutaneous immediate hypersensitivity responses to both the experimental epitope mapping, we plan further studies in a larger cohort of HIV-infected persons, using peptides containing most of the and control antigens that resolved in õ1 h.
The histology at the sites of peptide-induced induration was described epitopes of the HIV-1 gp120 protein, to seek critical information on the cellular immunoregulation of HIV-1. characterized by superficial and deep perivascular and periadnexal inflammation ( figure 2C ). The lymphocytic infiltrate was There are potential limitations to this technique. Both volunteers tested in this study had preserved standard recall DTH responfound to be primarily CD3 / (data not shown), with a preponderance of CD4 cells ( figure 2D ). This pattern of lymphocytic siveness and were therefore not anergic. This technique would be unlikely to provide information in immunodeficient persons who infiltration, with the absence of a granulocytic component, is consistent with previous descriptions of DTH reactions [9] .
were anergic to common recall antigens. In addition, should a large number of peptides be required to adequately cover a protein HIV-1 envelope-specific CD4 T lymphocyte lines from both volunteers proliferated in response to the appropriate sequence, it may be necessary to initially pool groups of peptides and subsequently separate the reactive pools in a second applica-V3 loop peptides when evaluated Ç6 months prior to skin testing; results from volunteer 2 are shown as an example tion, making this technique more time-consuming. Despite these potential limitations, the DTH peptide skin ( figure 1A ). Because the CD4 T lymphocyte lines were generated in vitro by repetitive antigen stimulation and interleukintesting technique offers numerous advantages over currently available in vitro techniques to define the regions of cellular 2 expansion, it can only be concluded that there were precursors present in the hosts capable of responding to those immunoreactivity: It is potentially more specific than CD4 T lymphocyte lines and therefore more informative of the in vivo particular epitopes. It should not be assumed that these responding cells are expanded in vivo, since there have been state, since it measures expanded lymphocyte populations and not in vitro expanded precursors; it is potentially more sensireports of HIV-1 -specific CD4 T lymphocyte lines generated from uninfected low-risk subjects [10] .
tive, as suggested by our comparison to contemporaneous PBMC proliferation, since the entire lymphocyte population of When PBMC proliferation was assayed as a surrogate for in vivo expanded CD4 cell populations, there was a loss of the host is capable of responding and not just a small venous aliquot; it is a simple, well-established, clinical technique that since results are available in 48 h instead of a week (PBMC proliferation) to months (CD4 T lymphocyte line development) requires no laboratory training and could therefore be utilized in remote regions of the world where laboratory facilities are of laboratory effort; and it should be relatively inexpensive once it is commercially available. unavailable; it could provide rapid results in large cohorts, 
